Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its primary small molecule product candidates include CereKin, an oral interleukin-1 beta inhibitor for osteoarthritis pain and inflammation in dogs; AtoKin, a beef-flavored formulation of fexofenadine for atopic dermatitis in dogs; and SentiKin, an oral analgesic formulation of flupirtine to manage post-operative pain in dogs, cats, and horses. The company's other small molecule product candidates consist of KIND-007, an inhibitor of Bruton’s t...
1499 Bayshore Highway
Burlingame, CA 94010
Founded in 2012
Kindred Biosciences Mulls Acquisition
Jan 16 15
Kindred Biosciences, Inc. (NasdaqCM:KIN) is seeking acquisition. Kindred Biosciences, Inc. has filed a Shelf Registration in the amount of $150.00 million. Kindred Biosciences may use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to company’s own. Pending these uses, the net proceeds will be invested in investment-grade, interest-bearing securities.
Kindred Biosciences, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 05:00 PM
Nov 17 14
Kindred Biosciences, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 05:00 PM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.
Kindred Biosciences, Inc. Announces Unaudited Financial Results for the Third Quarter and Nine Months Ended September 30, 2014; Receives Approval from FDA for AtoKin's New Animal Drug Application Phase 1 CMC Technical Section
Nov 13 14
Kindred Biosciences, Inc. announced unaudited financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported loss from operations of USD 6,097,000 against USD 1,212,000 a year ago. Interest income was USD 25,000 against USD 2,000 a year ago. Net loss was USD 6,072,000 against USD 1,210,000 a year ago. Net loss per share, basic and diluted was USD 0.31 against USD 0.40 a year ago.
For the nine months, the company reported loss from operations of USD 20,417,000 against USD 1,832,000 a year ago. Interest income was USD 67,000 against USD 2,000 a year ago. Net loss was USD 20,350,000 against USD 1,830,000 a year ago. Net loss per share, basic and diluted was USD 1.10 against USD 0.61 a year ago.
The company has received approval from the FDA for AtoKin's New Animal Drug Application Phase 1 CMC Technical Section. The company has initiated several additional programs, including SentiKin for osteoarthritis in dogs, SentiKin for dental extraction, and KIND-011 for metabolic syndrome in horses. AtoKin and SentiKin programs continue to enroll rapidly and remain on track for completion in 2015. Other programs, including programs for inappetance in cats, postoperative pain in cats, KIND-012 for fever in horses, and feline erythropoeitin, continue to advance as previously planned.